Pharmaceuticals

Op-Ed
August 25, 2023
RealClearHealth

Too Fast or Too Slow: Ambivalence about Drug Development Affects Health

By Kirsten Axelsen
Op-Ed
August 22, 2023
The Wall Street Journal

‘Programmable Planet’ Review: Biology’s Big Bonus

By David Shaywitz
Report
August 08, 2023
Social Science Research Network

Rationing Medicine Through Bureaucracy: Authorization Restrictions in Medicare

By Boris Vabson | Zarek Brot-Goldberg | Samantha Burn | Timothy Layton
Op-Ed
August 04, 2023
The Wall Street Journal

‘The Good Virus’ Review: An Unlikely Healer

By David Shaywitz
Post
August 04, 2023
AEIdeas

Prior Authorization Reduces Net Costs of Medicare Part D

By Boris Vabson
Press
June 28, 2023

Discussing the latest A.I. advances in drug design and heatlhcare: Gottlieb on CNBC’s ‘Squawk Box’

By Scott Gottlieb
Op-Ed
June 20, 2023
RealClearHealth

Are Intermediaries Necessary for Better, More Cost-Effective Healthcare Delivery?

By Kirsten Axelsen | Cathy DuRei
Op-Ed
June 05, 2023
Timmerman Report

Pharma R&D Execs Offer Extravagant Expectations for AI but Provide Few Proof Points

By David Shaywitz
Press
May 23, 2023

Discussing the proliferation of weight loss drugs: Gottlieb on CNBC’s ‘The Exchange’

By Scott Gottlieb
Op-Ed
Pharmaceuticals
May 16, 2023
Timmerman Report

Biopharma Innovation – Beyond The Breathless Headlines

By David Shaywitz
Op-Ed
April 09, 2023
Timmerman Report

Tech, Pharma, and The Uneven Distribution of the AI-Enabled Future

By David Shaywitz
Press
April 06, 2023

Discussing investing in pharmaceuticals and J&J’s $8.9 billion talc product settlement: Gottlieb on CNBC’s ‘Power Lunch’

By Scott Gottlieb
Op-Ed
April 03, 2023
Washington Examiner

Medicine price setting might appeal to voters but will cost patients

By Kirsten Axelsen | Michael W. Hodin
Op-Ed
February 26, 2023
Timmerman Report

The Success of Your Tech Deployment Depends on a Role You’ve Probably Never Heard Of 

By David Shaywitz
Post
February 07, 2023
AEIdeas

How Medicare Shapes Drug Prices

By Benedic N. Ippolito | Joseph Levy
Op-Ed
February 04, 2023
Timmerman Report

Grand Défi Ou Goulot D’étranglement Ultime: A French Pharma Tackles Data Science

By David Shaywitz
Post
February 03, 2023
AEIdeas

The Inflation Reduction Act: Implications for Private-Sector Initiatives

By Kirsten Axelsen
Post
February 01, 2023
AEIdeas

Initial Implications from the Pricing of Humira Biosimilars

By Scott Gottlieb | Benedic N. Ippolito
Event
Overhead shot of pharmacy and customers
January 27, 2023

The Inflation Reduction Act: Implications for Private-Sector Initiatives

By Kirsten Axelsen
Post
January 05, 2023
AEIdeas

Inflation Reduction Act: Discussion About the Mixed Effect on Costs for Drugs with Amitabh Chandra and Craig Burton

By Kirsten Axelsen
Event
Person getting a shot from a doctor
January 10, 2023

Accurate Race and Ethnic Representation in Pivotal Clinical Drug Trials: Why It Matters and Potential Approaches to Achieve It

By Kirsten Axelsen
Post
November 28, 2022
AEIdeas

The Use of Evidence to Control Access and Cost of Pharmaceuticals

By Kirsten Axelsen
Event
Pharmaceutical lab
November 18, 2022

The Use of Evidence to Control Access and Cost of Pharmaceuticals

By Kirsten Axelsen | Amitabh Chandra
Event
September 22, 2022

Access to Obesity Care in the US: Coverage in a New Era of Treatments

By Kirsten Axelsen | Joseph Antos